High dose misonidazole with dexamethasone rescue: a possible approach to circumvent neurotoxicity.
With a view to modifying misonidazole (MISO) neurotoxicity, we initiated a randomized clinical study to assess a possible drug interaction and toxicity protection when dexamethasone (DXM) is administered concomittantly with MISO. The ongoing study consists of: 1. Pharmacokinetic evaluation; 2. Assessment of toxicity. Fourteen patients undergoing radiation therapy for different types of malignant neoplasia (excluding brain tumors) have been randomized to receive either MISO alone, or DXM one week prior and during treatment with MISO. Five of seven patients receiving MISO alone developed peripheral neuropathies while only one out of 7 patients that received MISO with DXM coverage developed a transient and mild neuropathy. Pharmacokinetic evaluation of MISO in plasma and urine of those patients receiving DXM has shown no evidence of drug interaction. It is postulated that the mechanism of action of DXM is at the nerve cell membrane level, restoring and stabilizing cell surface properties. In future studies we will investigate the use of DXM with increasing doses of MISO above the recommended maximum dose of 12 gm/m2, hoping to achieve a higher tumor tissue level of MISO while avoiding unacceptable toxicity. The effect of Allopurinol on the plasma kinetics of MISO was studied in four additional patients, observing also no evidence of drug interaction.
D000493:Allopurinol / Q000494:pharmacology; D003907:Dexamethasone / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D008920:Misonidazole / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D009369:Neoplasms / Q000532:radiotherapy*; D009422:Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control*; D009593:Nitroimidazoles / Q000627:therapeutic use*; D013997:Time Factors
D009593:Nitroimidazoles; D000493:Allopurinol; D003907:Dexamethasone; D008920:Misonidazole